<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03981003</url>
  </required_header>
  <id_info>
    <org_study_id>CIVI/2018/ET-02</org_study_id>
    <nct_id>NCT03981003</nct_id>
  </id_info>
  <brief_title>Serum Neurofilament-light Chain Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis</brief_title>
  <acronym>NeurofilMS</acronym>
  <official_title>Serum Neurofilament-light Chain Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute for Regenerative Medicine and Biotherapy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that serum neurofilament-light chain (NfL) levels can provide
      information about the level of activity and progression of Multiple Sclerosis at different
      stages and landmarks of the disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 22, 2019</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease</measure>
    <time_frame>Inclusion</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease</measure>
    <time_frame>6 months</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease</measure>
    <time_frame>12 months</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease</measure>
    <time_frame>18 months</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease</measure>
    <time_frame>2 years</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.</measure>
    <time_frame>Inclusion</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.</measure>
    <time_frame>6 months</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.</measure>
    <time_frame>1 year</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.</measure>
    <time_frame>18 months</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.</measure>
    <time_frame>2 years</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients</measure>
    <time_frame>Inclusion</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients</measure>
    <time_frame>6 months</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients</measure>
    <time_frame>1 year</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients</measure>
    <time_frame>18 months</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients</measure>
    <time_frame>2 years</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with relapse compared to stable patients</measure>
    <time_frame>Inclusion</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with relapse compared to stable patients</measure>
    <time_frame>6 months</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with relapse compared to stable patients</measure>
    <time_frame>1 year</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with relapse compared to stable patients</measure>
    <time_frame>18 months</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with relapse compared to stable patients</measure>
    <time_frame>2 years</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with isolated MRI activity compared to stable patients</measure>
    <time_frame>Inclusion</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with isolated MRI activity compared to stable patients</measure>
    <time_frame>6 months</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with isolated MRI activity compared to stable patients</measure>
    <time_frame>1 year</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with isolated MRI activity compared to stable patients</measure>
    <time_frame>18 months</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with isolated MRI activity compared to stable patients</measure>
    <time_frame>2 years</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients</measure>
    <time_frame>Inclusion</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients</measure>
    <time_frame>6 months</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients</measure>
    <time_frame>1 year</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients</measure>
    <time_frame>18 months</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients</measure>
    <time_frame>2 year</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients</measure>
    <time_frame>Inclusion</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients</measure>
    <time_frame>6 months</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients</measure>
    <time_frame>1 year</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients</measure>
    <time_frame>18 months</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients</measure>
    <time_frame>2 years</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort</measure>
    <time_frame>Inclusion</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort</measure>
    <time_frame>6 months</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort</measure>
    <time_frame>1 year</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort</measure>
    <time_frame>18 months</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort</measure>
    <time_frame>2 years</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease</measure>
    <time_frame>Inclusion</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease</measure>
    <time_frame>6 months</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease</measure>
    <time_frame>1 year</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease</measure>
    <time_frame>18 months</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease</measure>
    <time_frame>2 years</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with disease evolution (relapse, disability progression or MRI activity)</measure>
    <time_frame>Inclusion</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with disease evolution (relapse, disability progression or MRI activity)</measure>
    <time_frame>6 months</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with disease evolution (relapse, disability progression or MRI activity)</measure>
    <time_frame>1 year</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with disease evolution (relapse, disability progression or MRI activity)</measure>
    <time_frame>18 months</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with disease evolution (relapse, disability progression or MRI activity)</measure>
    <time_frame>2 years</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity)</measure>
    <time_frame>Inclusion</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with disease activity (relapse, or MRI activity)</measure>
    <time_frame>6 months</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity)</measure>
    <time_frame>1 year</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity)</measure>
    <time_frame>18 months</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity)</measure>
    <time_frame>2 years</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with relapses</measure>
    <time_frame>Inclusion</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with relapses</measure>
    <time_frame>6 months</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with relapses</measure>
    <time_frame>1 year</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with relapses</measure>
    <time_frame>18 months</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with relapses</measure>
    <time_frame>2 years</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with MRI activity</measure>
    <time_frame>Inclusion</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with MRI activity</measure>
    <time_frame>6 months</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with MRI activity</measure>
    <time_frame>1 year</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with MRI activity</measure>
    <time_frame>18 months</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with MRI activity</measure>
    <time_frame>2 years</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement</measure>
    <time_frame>Inclusion</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement</measure>
    <time_frame>6 months</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement</measure>
    <time_frame>1 year</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement</measure>
    <time_frame>18 months</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement</measure>
    <time_frame>2 years</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement</measure>
    <time_frame>Inclusion</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement</measure>
    <time_frame>6 months</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement</measure>
    <time_frame>1 year</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement</measure>
    <time_frame>18 months</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement</measure>
    <time_frame>2 years</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of disability</measure>
    <time_frame>Inclusion</time_frame>
    <description>Expanded Disability Status Scale (EDSS); scale 1= no disability to 10 = death from multiple sclerosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of disability</measure>
    <time_frame>Relapse (measured up to 2 years)</time_frame>
    <description>Expanded Disability Status Scale (EDSS); scale 1= no disability to 10 = death from multiple sclerosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of multiple sclerosis</measure>
    <time_frame>EDSS progression (measured up to 2 years)</time_frame>
    <description>Multiple Sclerosis Functional Composite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of multiple sclerosis</measure>
    <time_frame>Active MRI (measured up to 2 years)</time_frame>
    <description>Multiple Sclerosis Functional Composite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Generic health status</measure>
    <time_frame>Inclusion</time_frame>
    <description>EuroQol 5 dimension questionnaire (EQ-5D)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Generic health status</measure>
    <time_frame>Relapse (measured up to 2 years)</time_frame>
    <description>EuroQol 5 dimension questionnaire (EQ-5D)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Generic health status</measure>
    <time_frame>EDSS progression (measured up to 2 years)</time_frame>
    <description>EuroQol 5 dimension questionnaire (EQ-5D)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Generic health status</measure>
    <time_frame>active MRI (measured up to 2 years)</time_frame>
    <description>EuroQol 5 dimension questionnaire (EQ-5D)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Disease Modifying Drugs</measure>
    <time_frame>Inclusion</time_frame>
    <description>Categorized by class type of treatment (1st line, 2nd line and 3rd line therapies)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Disease Modifying Drugs</measure>
    <time_frame>6 monrths</time_frame>
    <description>Categorized by class type of treatment (1st line, 2nd line and 3rd line therapies)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Disease Modifying Drugs</measure>
    <time_frame>1 year</time_frame>
    <description>Categorized by class type of treatment (1st line, 2nd line and 3rd line therapies)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Disease Modifying Drugs</measure>
    <time_frame>18 months</time_frame>
    <description>Categorized by class type of treatment (1st line, 2nd line and 3rd line therapies)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Disease Modifying Drugs</measure>
    <time_frame>2 years</time_frame>
    <description>Categorized by class type of treatment (1st line, 2nd line and 3rd line therapies)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain in 800 patients from the OFSEP cohort including Multiple Sclerosis patients at different stages and Neuromyelitis optica spectrum disorder patients</measure>
    <time_frame>Inclusion</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain in 800 patients from the OFSEP cohort including Multiple Sclerosis patients at different stages and Neuromyelitis optica spectrum disorder patients</measure>
    <time_frame>Month 6</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain in 400 patients from the OFSEP cohort with a Clinically Isolated Syndrome at inclusion</measure>
    <time_frame>Inclusion</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurofilament Light Chain in 400 patients from the OFSEP cohort with a Clinically Isolated Syndrome at inclusion</measure>
    <time_frame>Month 6</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Create biobank</measure>
    <time_frame>Inclusion</time_frame>
    <description>Blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Create biobank</measure>
    <time_frame>6 months</time_frame>
    <description>Blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Create biobank</measure>
    <time_frame>1 year</time_frame>
    <description>Blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Create biobank</measure>
    <time_frame>18 months</time_frame>
    <description>Blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Create biobank</measure>
    <time_frame>2 years</time_frame>
    <description>Blood samples</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1750</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>MS Patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>2 x 4 ml tubes blood to screen for serum Neurofilament Light Chain levels</description>
    <arm_group_label>MS Patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population is composed of consecutive patients over 15 years of age, of both
        sexes, recruited during consultations for a CIS, RRMS or progressive MS at the Neurology
        department of 30 OFSEP centres and of Nîmes and Nantes University Hospitals. The patients
        recruited will have an EDSS score comprised between 0 - 7.0.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient has been correctly informed.

          -  The patient must have given their informed and signed consent.

          -  The patient must be insured or beneficiary of a health insurance plan.

          -  The patient is at least (≥)15 years old.

          -  The patient has MS according to diagnosis criteria (Thompson et al. 2017) and:

               -  Participates to the OFSEP-HD cohort (ancillary study);

               -  Has a Expanded Disability Status Scale score comprised between 0 - 7.0;

               -  With or without Disease Modifying Drug;

               -  For Work Package 3: patients enrolled in any OFSEP-HD centre that meet landmark
                  criteria for an active MS (relapse, or Expanded Disability Status Scale
                  progression, or active MRI) during follow-up;

               -  For Work Package 4: patients with a stable disease enrolled in OFSEP-HD study in
                  Nîmes or Nantes University Hospitals.

        Exclusion Criteria:

          -  Within the past three months, the patient has participated in another interventional
             study that may interfere with the results or conclusions of this study.

          -  The patient is in an exclusion period determined by a previous study.

          -  The patient is under judicial protection.

          -  The patient refuses to sign the consent.

          -  It is impossible to correctly inform the patient (inability to understand the study,
             language problem).

          -  The patient is pregnant or breast-feeding.

          -  The patient is under 15 years old.

          -  Inability to answer questionnaires.

          -  Clinically isolated syndrome (CIS) that does not meet the criteria of MS.

          -  Radiologically isolated syndrome (RIS).

          -  Patient with Neuromyelitis optica spectrum disorder.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Thouvenot</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nimes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric Thouvenot</last_name>
    <phone>+33.(0)4.66.68.32.61</phone>
    <email>eric.thouvenot@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU d'Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Abdullatif AL KHEDR</last_name>
      <email>AlKhedr.Abdullatif@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Abdullatif AL KHEDR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Besancon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric BERGER</last_name>
      <email>eberger@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Eric BERGER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruno BROCHET</last_name>
      <email>bruno.brochet@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno BROCHET</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aurélie RUET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nathalie DERACHE</last_name>
      <phone>02 31 06 46 17</phone>
      <email>derache-n@chu-caen.fr</email>
    </contact>
    <investigator>
      <last_name>Nathalie DERACHE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles DEFER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre CLAVELOU</last_name>
      <phone>04 73 75 22 01</phone>
      <email>pclavelou@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre CLAVELOU</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique AUFAUVRE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédéric TAITHE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier MOISSET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alain CREANGE</last_name>
      <email>alain.creange@hmn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Alain CREANGE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thibault MOREAU</last_name>
      <phone>03 80 29 55 84</phone>
      <email>thibault.moreau@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Thibault MOREAU</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Agnès FROMONT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique AUDRY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gwendoline DUPONT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier CASEZ</last_name>
      <phone>04 76 76 58 71</phone>
      <email>ocasez@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier CASEZ</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mathieu VAILLANT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick VERMERSCH</last_name>
      <phone>03 20 44 60 53</phone>
      <email>patrick.vermersch@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Patrick VERMERSCH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent MAGY</last_name>
      <phone>05 55 05 65 61</phone>
      <email>laurent.magy@unilim.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent MAGY</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexis MONTCUQUET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandra VUKUSIC</last_name>
      <phone>04.72.35.75.22</phone>
      <email>sandra.vukusic@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Sandra VUKUSIC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Françoise DURAND-DUBIEF</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean PELLETIER</last_name>
      <email>jean.pelletier@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Jean PELLETIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre LABAUGE</last_name>
      <email>labauge@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre LABAUGE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier AYRIGNAC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clarisse CARRA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc DEBOUVERIE</last_name>
      <email>m.debouverie@chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Marc DEBOUVERIE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie PITTION VOUYOVITCH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine Lebrun-Frenay</last_name>
      <phone>04 92 03 78 98</phone>
      <email>lebrun.c@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Christine Lebrun-Frenay</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Veronique Bourg</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mikaël Cohen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nimes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anissa Megzari</last_name>
      <phone>04.66.68.42.36</phone>
      <email>drc@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Eric Thouvenot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondation Rothschild</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier GOUT</last_name>
      <email>ogout@fo-rothschild.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier GOUT</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Romain DESCHAMPS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine LUBETZKI</last_name>
      <email>catherine.lubetzki@psl.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Catherine LUBETZKI</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline PAPEIX</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruno Prénom Bruno Bruno STANKOFF</last_name>
      <email>bruno.stankoff@sat.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno STANKOFF</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Poissy</name>
      <address>
        <city>Poissy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier HEINZLEF</last_name>
      <phone>01 39 27 41 81</phone>
      <email>oheinzlef@chi-poissy-st-germain.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier HEINZLEF</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Potiers</name>
      <address>
        <city>Potiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean Philippe NEAU</last_name>
      <phone>05 49 44 44 46</phone>
      <email>jean-philippe.neau@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Jean Philippe NEAU</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lauriane CHAMBRIER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas MAUBEUGE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fanny SOURDRILLE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emanuelle LE PAGE</last_name>
      <email>infirmieres.recherche-clinique@chu-rennes.Fr</email>
    </contact>
    <investigator>
      <last_name>Emanuelle LE PAGE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles EDAN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr MICHEL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bertrand BOURRE</last_name>
      <phone>02 32 88 33 99</phone>
      <email>bertrand.bourre@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>Bertrand BOURRE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Saint Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean Philippe CAMDESSANCHE</last_name>
      <phone>04 77 12 78 05</phone>
      <email>j.philippe.camdessanche@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Jean Philippe CAMDESSANCHE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jérôme DE SEZE</last_name>
      <phone>03 88 12 85 44</phone>
      <email>jerome.de.seze@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Jérôme DE SEZE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Damien BIOTTI</last_name>
      <email>biotti.d@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Damien BIOTTI</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan CIRON</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne-Marie GUENNOC</last_name>
      <phone>02 47 47 80 23</phone>
      <email>guennoc@univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Anne-Marie GUENNOC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Martinique</name>
      <address>
        <city>Fort-de-France</city>
        <country>Martinique</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe CABRE</last_name>
      <email>pcabre_fr@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe CABRE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emeline Berthelot</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Martinique</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>June 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2019</study_first_posted>
  <last_update_submitted>August 2, 2019</last_update_submitted>
  <last_update_submitted_qc>August 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

